{"id":290,"date":"2020-03-19T16:54:00","date_gmt":"2020-03-19T07:54:00","guid":{"rendered":"https:\/\/www.ssri.com\/china\/e\/chinanews\/?p=290"},"modified":"2020-03-19T16:54:00","modified_gmt":"2020-03-19T07:54:00","slug":"pfizer-astrazeneca-and-bayer-are-the-top-3-companies-for-sales-rep-visitations","status":"publish","type":"post","link":"https:\/\/www.ssri.com\/china\/e\/chinanews\/290","title":{"rendered":"Pfizer, AstraZeneca and Bayer are the top 3 companies for sales rep visitations"},"content":{"rendered":"<p>According to PatientsMap CN 2019 data which asks doctors about sales reps that have visited them in the past month for 64 pharmaceutical companies, approximately 1\/3 of the 12,000 physicians in China have answered that they met a sales rep from Pfizer and AstraZeneca in the past month.\u00a0\u00a0Below table shows the top 10 pharmaceutical companies with the highest sales rep visitation rates overall.<\/p>\n<p>Compared to 2018 data, while the top 4 companies remain unchanged, we see more domestic pharma companies in the top 10 (2 companies in 2018 vs. 4 companies in 2019), and CTTQ pharmaceutical moved from 8<sup>th<\/sup> to 5<sup>th<\/sup>.\u00a0 In particular for the oncology area, there are 5 domestic pharma companies in the top 10 sales rep visits, with the top being a domestic company Hengrui with 50.2% sales rep visitation rate.\u00a0This may suggest that the domestic companies are starting to enhance their sales force activities.<\/p>\n<p>The highest ranked Japanese companies were Eisai (25th with 7.2%), Takeda (27<sup>th<\/sup> with 5.3%) and Daiichi Sankyo (29<sup>th<\/sup> with 4.9%).<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"alignnone  wp-image-288\" src=\"https:\/\/www.ssri.com\/china\/e\/chinanews\/wp-content\/uploads\/sites\/3\/2020\/03\/top10.jpg\" alt=\"\" width=\"555\" height=\"289\" srcset=\"https:\/\/www.ssri.com\/china\/e\/chinanews\/wp-content\/uploads\/sites\/3\/2020\/03\/top10.jpg 680w, https:\/\/www.ssri.com\/china\/e\/chinanews\/wp-content\/uploads\/sites\/3\/2020\/03\/top10-300x156.jpg 300w\" sizes=\"auto, (max-width: 555px) 100vw, 555px\" \/>&nbsp;<\/p>\n<p><u>For more information about PatientsMap CN 2019, please see below:<\/u><\/p>\n","protected":false},"excerpt":{"rendered":"<p>According to PatientsMap CN 2019 data which asks doctors about sales reps that have visited them in the past month for 64 pharmaceutical companies, approximately 1\/3 of the 12,000 physicians in China have answered that they met a sales rep from Pfizer and AstraZeneca in the past month.\u00a0\u00a0Below table shows the top 10 pharmaceutical companies with the highest sales rep visitation rates overall. Compared to 2018 data, while the top 4 companies remain unchanged, we see more domestic pharma companies in the top 10 (2 companies in 2018 vs. 4 companies in 2019), and CTTQ pharmaceutical moved from 8th to 5th.\u00a0 In particular for the oncology area, there are 5...  <a class=\"excerpt-read-more\" href=\"https:\/\/www.ssri.com\/china\/e\/chinanews\/290\" title=\"Read Pfizer, AstraZeneca and Bayer are the top 3 companies for sales rep visitations\">Read more &raquo;<\/a><\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-290","post","type-post","status-publish","format-standard","hentry","category-chinanews"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/www.ssri.com\/china\/e\/chinanews\/wp-json\/wp\/v2\/posts\/290","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ssri.com\/china\/e\/chinanews\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ssri.com\/china\/e\/chinanews\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ssri.com\/china\/e\/chinanews\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ssri.com\/china\/e\/chinanews\/wp-json\/wp\/v2\/comments?post=290"}],"version-history":[{"count":5,"href":"https:\/\/www.ssri.com\/china\/e\/chinanews\/wp-json\/wp\/v2\/posts\/290\/revisions"}],"predecessor-version":[{"id":295,"href":"https:\/\/www.ssri.com\/china\/e\/chinanews\/wp-json\/wp\/v2\/posts\/290\/revisions\/295"}],"wp:attachment":[{"href":"https:\/\/www.ssri.com\/china\/e\/chinanews\/wp-json\/wp\/v2\/media?parent=290"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ssri.com\/china\/e\/chinanews\/wp-json\/wp\/v2\/categories?post=290"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ssri.com\/china\/e\/chinanews\/wp-json\/wp\/v2\/tags?post=290"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}